Genetically Modified Cells TRIZ Cases

Single-cell profiling resolves choroid plexus heterogeneity to identify markers and therapeutic targets for oxidative stress and neurologic disease.

A CMV-IFNγ-HTLV chimeric promoter boosts stable gene expression in activated T cells while remaining low in non-immune cells.

A humanized TfR and GAA-knockout animal model enables more reliable testing of therapeutic intracellularization and transport across the BBB.

IL-4 and a TGF-βR agonist expand pluripotent stem cell-derived regulatory T cells while maintaining suppressive function.

A two-stage hPSC differentiation process generates NK and γδ NKT cells at scale without CD34+ enrichment or spin EB formation.

A Nectin-4-specific antibody improves sensitive, specific detection across ELISA, flow cytometry, Western blot, and tissue staining for cancer diagnosis.

Engineered AAVhu68 capsid coding sequences raise recombinant vector yield while preserving packaging efficiency in host-cell production.

GLIS gene introduction enables direct somatic cell conversion with shorter culture time, better reproducibility, and no stem cell stage.

Blocking TIGIT binding to CD155 relieves tumor immunosuppression, boosts immune cell anti-tumor activity, and may limit secondary resistance.

Gene-edited iPSCs generate functional, immune-compatible platelets ex vivo to overcome donor shortages and short platelet shelf life.

Direct delivery of master regulator proteins such as BAZ2B helps distinguish causal reprogramming drivers and generate multipotent stem cells.

Staged iPSC differentiation with CD34+ enrichment, EHT, and tuned culture conditions improves erythroid expansion and enucleation ex vivo.

Targeted CHO cell knockouts reduce lipase and hydrolase activity, lowering purification burden and protecting recombinant protein shelf-life.

By inhibiting SIRT2 in CAR T cells, this case boosts aerobic glycolysis and effector function to improve tumor rejection in harsh microenvironments.

Genetically modified cell lines enable FRET assays to distinguish BoNT serotypes with shared SNARE targets, without antibodies or heavy chains.

Fluorescence-based sorting replaces MTX or MSX selection to enrich high-titer producer cells faster while preserving viability and clonal stability.

Operably linked pseudogenes diversify autonomous heavy chain antibody domains through gene conversion while preserving antigen-binding function.

O-linked glycosylation at selected light-chain residues raises antibody productivity and yield while maintaining titer and biological activity.

Amphiphilic PEG-PVAc-PVCap graft copolymers protect cultured cells from shear stress while avoiding aldehyde impurities that harm viability and antibody stability.

Controlled multi-step cooling and rapid orbital-shaker thawing limit ice crystal damage and preserve immune cell viability after storage.

Raising phosphate and potassium in animal cell culture medium improves viable cell density, extends culture time, and boosts protein production.

An OLIG2 S147 mutant combined with SOX10 drives faster, more consistent oligodendrocyte-like cell differentiation while limiting astrocyte and motor neuron induction.

Keeping aromatic metabolites below 3 mM and key amino acids below 2 mM helps sustain mammalian cell growth, density, and protein output.

A selection marker placed outside transposon ITRs enables transient selection, preserves proliferation capacity, and lowers cultured meat cell costs.

By overexpressing Mbnl2 and related regulators, stem cell-derived neurons reach mature states faster for late-onset disease modeling.

Alternating high and low glucose with glucokinase activation sustains Mycl-driven pancreatic islet cell proliferation across repeated subcultures.

Cryopreserved PSC expansion enables on-demand neural cell production at industrial scale, cutting cost and improving assay-ready cell availability.

Orthogonal tRNA synthetase engineering plus apoptosis gene knockout boosts non-natural amino acid protein yield by improving mammalian cell viability.

Introducing MYCT1 and controlling endocytosis helps expand hematopoietic stem cells ex vivo without losing self-renewal or engraftment.

Targeting defined open chromatin regions in RPE cells enables stable, high-level therapeutic polypeptide expression with less cell line screening.

A pre-differentiation stage with Notch ligands and REV-ERB inhibition boosts CD16+ NK cell yield and ADCC without gene insertion.

Epigenetic reprogramming and gene-vector enhancement help adult stem cells reverse age-related functional loss and restore cognition.

Selective killing of non-megakaryocyte cells stabilizes phenotype and raises platelet output in serum- and feeder-free culture.

Bax/Bak-deficient HEK293 cells resist shear stress and apoptosis, sustaining viability and polypeptide or viral vector production in bioreactors.

Specific growth-factor culture expands and enriches disc stem cells that survive the disc environment and support long-term tissue regeneration.

Introducing FIGLA, NOBOX, LHX8, and TBPL2 speeds pluripotent cell differentiation into immature oocytes within 5-10 days.

A 3D biodegradable scaffold with fibroblasts and ECM enables cruelty-free leather formation while supporting cell growth and tissue integration.

A fluorescent Amalthea feeder cell line boosts EBV B-cell transformation and enables direct monoclonal antibody isolation without subcloning.

FACS enriches rare antigen-specific cells by binding strength, cutting hybridoma screening time and isolating high-affinity antibodies faster.

Heat shock promoters replace unsafe inducers to control muscle and fat differentiation in edible avian and bovine cell cultures.

Genetically reducing HLA expression in iPSC-derived macrophages enables universal cell therapy while preserving anti-inflammatory and anti-fibrotic function.

Grouping media components by pH and solubility cuts acid and base use, lowering metal contamination and lot-to-lot variation in liquid media.

Glycine, with optional cysteine, helps high-density megakaryocyte culture raise platelet yield without losing platelet bioactivity.

Transient ETV2 mRNA expression replaces serum and feeder layers to scale hiPSC-derived neutrophil and macrophage production under GMP-ready conditions.

Irradiated feeder cells and recombinant IL-2 expand scarce FcRγ-deficient NK cells up to 1000-fold while preserving therapeutic phenotype.

A systematic TFome ORF screen drives hiPSCs into specific cell types with less heterogeneity and more robust differentiation.

Forced expression of oncogene, homeobox, and apoptosis inhibitor genes enables expandable megakaryocyte lines for platelet supply.

Targeted suppression of genes such as RASA2 and TIGIT boosts immune cell proliferation, cytokine release, and tumor killing after infusion.

Dynamic poloxamer-188 dosing in perfusion culture balances high mammalian cell density with recombinant protein stability.

A 79th-residue alanine or glycine substitution shifts exporter specificity toward L-tyrosine, improving microbial export and production.

Specific cationic and structured lipid particles improve nucleic acid delivery into cardiomyocytes while enabling selective purification of cardiac muscle cells.